EUVIMEDOpdag EUVIMED
VergleichsstudieKohortenstudieOpen access · CC BY-NC-ND 4.0

Association of Sodium‐Glucose Cotransporter‐2 Inhibitors With Incident Gout Risk: A Population‐Based Comparative Cohort Study With Genetic Evidence From Mendelian Randomisation

Hong Sang Choi iD, Jaejun Heo iD, Sungho Won iD, Sang Heon Suh iD, Chang Seong Kim iD, Eun Hui Bae iD, Juhee Ahn iD, Soo Wan Kim iD

Diabetes, Obesity and Metabolism · 2026-09 · 28 (9) · 8230-8241

DOI: 10.1111/dom.71027 ↗

At a glance

Vergleichsstudie in Diabetes, Obesity and Metabolism, published online on 2026-06-21. Written by Hong Sang Choi and 7 co-authors. Institution: Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea. Major MEDLINE topics: Gout, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2. 34 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: National Research Foundation of Korea, Korea Health Industry Development Institute.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Aim

Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are known to reduce serum urate levels, yet their specific impact on gout incidence in the Korean population remains underexplored. We investigated the association between SGLT2i use and incident gout using real‐world data and Mendelian randomisation (MR) analysis. Materials and Methods We conducted a population‐based cohort study using the Korean National Health Insurance Service database (2015–2020). New users of SGLT2i were compared to dipeptidyl peptidase‐4 inhibitor (DPP4i) users. After 1:1 propensity score matching (PSM), 20 866 pairs were analysed using Cox proportional hazards models. The primary outcome was incident gout. Additionally, a two‐sample MR analysis utilised genetic variants in SLC5A2 as proxies for SGLT2 inhibition and gout summary statistics from the FinnGen consortium.

Results

In the cohort study, SGLT2i use was associated with a significantly lower risk of gout compared to DPP4i (incidence rate: 2792.6 vs. 3346.7 per 100 000 person‐years). The hazard ratio in the PSM model was 0.80 (95% confidence interval [CI] 0.76–0.84, p value < 0.001). This finding was robust across multiple sensitivity analyses, including landmark and time‐varying exposure models. In the MR analysis, genetically proxied SGLT2 inhibition was associated with a reduced risk of gout (odds ratio 0.10 per 1‐standard deviation decrease in HbA1c; 95% CI: 0.017–0.463; p value < 0.001), with consistent results across robust MR methods.

Conclusion

SGLT2i therapy is associated with a lower risk of incident gout compared to DPP4i in patients with type 2 diabetes. While these findings suggest potential pleiotropic effects of SGLT2i beyond glucose control, they should be interpreted with caution given the limitations of observational study designs.

Subjects

MeSH terms (MEDLINE)

GoutSodium-Glucose Transporter 2 InhibitorsDiabetes Mellitus, Type 2HumansMendelian Randomization AnalysisIncidenceMaleFemaleCohort StudiesMiddle AgedRepublic of KoreaDipeptidyl-Peptidase IV InhibitorsSodium-Glucose Transporter 2AgedAdult

Author keywords

diabetes mellitusdipeptidyl peptidase 4 inhibitorgoutmendelian randomisationsodium glucose cotransporter 2 inhibitor

Substances

Sodium-Glucose Transporter 2 InhibitorsDipeptidyl-Peptidase IV InhibitorsSLC5A2 protein, humanSodium-Glucose Transporter 2

Authors and institutions

  • Department of Internal Medicine, Chonnam National University Medical School, Gwangju, Republic of Korea.
  • Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Republic of Korea.
  • Department of Public Health Sciences, Graduate School of Public Health, Seoul National University, Seoul, Republic of Korea.
  • Institute of Health and Environment, Seoul National University, Seoul, Republic of Korea.
  • Division of Data Science, College of Intelligent Software Convergence, University of Suwon, Hwaseong-si, Gyeonggi-do, Republic of Korea.

ORCID profiles: Hong Sang Choi, Jaejun Heo, Sungho Won, Sang Heon Suh, Chang Seong Kim, Eun Hui Bae, Juhee Ahn, Soo Wan Kim

Funding

  • National Research Foundation of Korea
  • Korea Health Industry Development Institute

Cite

APA

Choi, H. S., Heo, J., Won, S., Suh, S. H., Kim, C. S., Bae, E. H., Ahn, J., & Kim, S. W. (2026). Association of Sodium‐Glucose Cotransporter‐2 Inhibitors With Incident Gout Risk: A Population‐Based Comparative Cohort Study With Genetic Evidence From Mendelian Randomisation. Diabetes, Obesity and Metabolism, 28(9), 8230-8241. https://doi.org/10.1111/dom.71027

Vancouver

Choi HS, Heo J, Won S, Suh SH, Kim CS, Bae EH, et al. Association of Sodium‐Glucose Cotransporter‐2 Inhibitors With Incident Gout Risk: A Population‐Based Comparative Cohort Study With Genetic Evidence From Mendelian Randomisation. Diabetes, Obesity and Metabolism. 2026;28(9):8230-8241. doi:10.1111/dom.71027

BibTeX
@article{Choi2026,
  author = {Choi, Hong Sang and Heo, Jaejun and Won, Sungho and Suh, Sang Heon and Kim, Chang Seong and Bae, Eun Hui and Ahn, Juhee and Kim, Soo Wan},
  title = {Association of Sodium‐Glucose Cotransporter‐2 Inhibitors With Incident Gout Risk: A Population‐Based Comparative Cohort Study With Genetic Evidence From Mendelian Randomisation},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  volume = {28},
  number = {9},
  pages = {8230--8241},
  doi = {10.1111/dom.71027}
}
Start for free →